The abovementioned LDL-C and non-high-density lipoprotein cholesterol lowering and safety findings in the subgroup of patients in ODYSSEY OUTCOMES with diabetes mellitus are consistent with those from the ODYSSEY DM-INSULIN41 and ODYSSEY DM-DYSLIPIDEMIA42 trials comparing alirocumab with placebo both in patients on maximum-tolerated statin and in patients with diabetes on insulin (both type 1 and type 2) and type 2 diabetes, respectively. This evidence concerns the gene INS and diabetes mellitus.